Northwest Biotherapeutics (NWBO) said that it discounted the exercise prices for certain warrant holders as an inducement to raise ~$1.3M in new capital. The company offered an exercise price of $0.35 a share for warrants to purchase up to 3,656,817 shares of common stock with original exercise prices of $4.50 - 6.00. In addition, Northwest issued new five-year Series E Warrants to the same warrant holders to purchase up to 3,656,817 shares of common stock at $0.41 a share. Net proceeds will fund the start of Phase 2 clinical trials and working capital.